The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension
Abstract
AIMS: The aims of this study were to evaluate the diagnostic value and to explore the prognostic value of N-terminal brain natriuretic peptide (N-TproBNP) in patients with systemic sclerosis (SSc) both with and without pulmonary arterial hypertension (PAH). METHODS AND RESULTS: N-TproBNP, six-minute walk distance (SMWD), haemodynamics (at right heart catheterization) or tricuspid gradient (by echocardiography), and survival were assessed in 109 patients with SSc. The study population included 68 individuals with PAH [mean pulmonary artery pressure (PAP) >25 mmHg and pulmonary capillary wedge pressure <15 mmHg] and 41 individuals without PAH. In patients with PAH, the prognostic value of baseline and change in WHO functional class, N-TproBNP levels, and SMWD were compared using Kaplan-Meier survival curves and Cox proportional hazard analysis. The mean duration of follow-up was 10 months (range 1-18 months). One year survival in patients with normal PAP was 100% when compared with 83.5% in those with SSc-PAH (P < 0.05). The patients without PAH had a mean N-TproBNP level of 139 pg/mL (SD 151); those with SSc-PAH had a significantly higher mean N-TproBNP level of 1474 pg/mL (SD 2642) (P = 0.0002). Among patients with PAH for every order of magnitude increase in N-TproBNP level there was a four-fold increased risk of death (P = 0.002 for baseline level and P = 0.006 for follow-up level). Baseline N-TproBNP levels were correlated positively with mean PAP (r = 0.62; P < 0.0001), pulmonary vascular resistance (PVR) (r = 0.81; P < 0.0001), and inversely with SMWD (r = -0.46; P < 0.0001). Among patients with SSc-PAH, 13 patients (19%) were in WHO functional classes II and had mean N-TproBNP levels of 325 pg/mL (SD 388). Fifty-three patients (78%) were in WHO classes III and IV and had significantly higher mean N-TproBNP levels of 1677 pg/mL (SD 2835) (P = 0.02). At an N-TproBNP level of 395 pg/mL, the sensitivity and specificity for predicting the presence of SSc-PAH were 56 and 95% respectively. CONCLUSION: Raised N-TproBNP levels are directly related to the severity of PAH. In screening programs, SSc patients with an N-TproBNP in excess of 395 pg/mL have a very high probability of having pulmonary hypertension. Baseline and serial changes in N-TproBNP levels are highly predictive of survival. A 10-fold increase in N-TproBNP level on therapy is associated with a greater than three-fold increase in mortality, and may indicate therapeutic failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure
Maisel, A. S., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., Abraham, W. T., Wu, A. H. B., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020233 · Cited by 3,362
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L., Smiseth, O. A., Gavazzi, A., Haverich, A., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi204 · Cited by 2,260
Modelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Clinical classification of pulmonary hypertension
Simonneau, G., Galiè, N., Rubin, L. J., Langleben, D., Seeger, W., Domenighetti, G., Gibbs, S., Lebrec, D., Speich, R., Beghetti, M., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.037 · Cited by 1,897
Mukoyama, M., Nakao, K., Hosoda, K., Suga, S., Saito, Y., Ogawa, Y., Shirakami, G., Jougasaki, M., Obata, K., & Yasue, H. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115146 · Cited by 1,354
MIYAMOTO, S., NAGAYA, N., SATOH, T., KYOTANI, S., SAKAMAKI, F., FUJITA, M., NAKANISHI, N., & MIYATAKE, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,154
B-type natriuretic peptide in cardiovascular disease
de Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13976-1 · Cited by 1,067
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,065
Cited by
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Guidelines for the diagnosis and treatment of pulmonary hypertension
(2009) · European Respiratory Journal · doi:10.1183/09031936.00139009 · Cited by 1,300
Diagnosis and Assessment of Pulmonary Arterial Hypertension
Badesch, D. B., Champion, H. C., Gomez Sanchez, M. A., Hoeper, M. M., Loyd, J. E., Manes, A., McGoon, M., Naeije, R., Olschewski, H., Oudiz, R. J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.011 · Cited by 1,138
Galiè, N., Rubin, L., Hoeper, M., Jansa, P., Al-Hiti, H., Meyer, G., Chiossi, E., Kusic-Pajic, A., & Simonneau, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60919-8 · Cited by 920
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
Coghlan, J. G., Denton, C. P., Grünig, E., Bonderman, D., Distler, O., Khanna, D., Müller-Ladner, U., Pope, J. E., Vonk, M. C., Doelberg, M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203301 · Cited by 832
Self-citation
Metadata
- Authors
- Williams, M. H., Handler, C. E., Akram, R., Smith, C. J., Das, C., Smee, J., Nair, D., Denton, C. P., Black, C. M., & Coghlan, J. G.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-04-27
- Volume
- 27
- Issue
- 12
- Pages
- 1485-1494
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2092661836
- Cited by
- 301
- References
- 34
- FWCI
- 18.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. https://app.cochat.ai/papers/10.1093/eurheartj/ehi891
- The paper
- Williams, M. H., Handler, C. E., Akram, R., Smith, C. J., Das, C., Smee, J., Nair, D., Denton, C. P., Black, C. M., & Coghlan, J. G. (2006). Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. European Heart Journal. https://doi.org/10.1093/eurheartj/ehi891
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.